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Abstract 
The diagnostic evaluation of acute chest pain has been augmented in recent years by advances in 
the sensitivity and precision of cardiac troponin assays, new biomarkers, improvements in 
imaging modalities, and release of new clinical decision algorithms.  This progress has enabled 
physicians to diagnose or rule-out acute myocardial infarction earlier after the initial patient 
presentation, usually in emergency department settings, which may facilitate prompt initiation of 
evidence-based treatments, investigation of alternative diagnoses for chest pain, or discharge, 
and permit better utilization of healthcare resources. A non-trivial proportion of patients fall in 
an indeterminate category according to rule-out algorithms, and minimal evidence-based 
guidance exists for the optimal evaluation, monitoring, and treatment of these patients.  The 
Cardiovascular Round Table of the ESC proposes approaches for the optimal application of early 
strategies in clinical practice to improve patient care following the review of recent advances in 
the early diagnosis of acute coronary syndrome.  The following specific “indeterminate” patient 
categories were considered:  1) patients with symptoms and high-sensitivity cardiac troponin 
<99
th
 percentile; 2) patients with symptoms and high-sensitivity troponin <99
th
 percentile but 
above the limit of detection; 3) patients with symptoms and high-sensitivity troponin >99
th
 
percentile but without dynamic change; and 4) patients with symptoms and high-sensitivity 
troponin >99
th
 percentile and dynamic change but without coronary plaque 
rupture/erosion/dissection.  Definitive evidence is currently lacking to manage these patients 
whose early diagnosis is “indeterminate” and these areas of uncertainty should be assigned a 
high priority for research.   
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INTRODUCTION 
 The diagnostic evaluation of acute chest pain has been augmented in recent years by 
advances in the sensitivity and precision of cardiac troponin (cTn) assays,
1
 improvements in 
imaging modalities, and release of new clinical decision algorithms.
2-7
  This progress has enabled 
physicians to diagnose or rule-out acute myocardial infarction (AMI) earlier after the initial 
presentation of patients in the emergency department with symptoms related to possible acute 
ischemia, which may facilitate prompt initiation of evidence-based treatments, investigation of 
alternative diagnoses for chest pain, or discharge, and permit better utilization of healthcare 
resources.
5;8
  It is also important to note that these protocols have not been evaluated in other 
hospitalized patient subsets (e.g., possible post-operative myocardial infarction, the critically ill, 
renal failure); thus, the scope of this manuscript is limited to emergency or acute care settings. 
 These advances have also introduced some challenges and opportunities.
9
  First, in 
addition to an earlier diagnosis, high sensitivity cardiac troponin (hs-cTn) assays also detect 
lower levels of circulating cTn, which has generated important discussions about the thresholds 
that should be implemented to identify myocardial necrosis, injury, or unstable angina, and to 
inform prognosis and treatment pathways or discharge decisions.  Second, several rule-out 
algorithms have been proposed and validated,
3;10-15
 three of which are recommended for use in 
the European Society of Cardiology (ESC) guideline for non-ST-elevation myocardial infarction 
(NSTEMI).
4
  Uncertainties remain about applying the algorithms to a broader population with 
possible AMI (e.g., patients with atypical symptoms, or early or late presenters).
2
  Applying 
these algorithms in this population, half of patients (40-60%) fall into the rule-out category, and 
thus into a group that potentially qualifies for earlier discharge after risk assessment.  However, a 
non-trivial proportion of patients (up to 44%)
2;3;12
 fall in an indeterminate category, and minimal 
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evidence-based guidance exists for the optimal evaluation, monitoring, and treatment of these 
patients.  Third, the advent of hs-cTn assays has shortened the timeline between symptom onset 
and interpretable biomarker results.  Thus, non-cardiologists (e.g., emergency department 
physicians or general practitioners) are increasingly engaged in making triage decisions based on 
rapid algorithms, but in general, these clinicians ask for guidance as they have not been involved 
in data collection or algorithm development.  In addition, the recent ESC guidelines on non-ST-
elevation acute coronary syndrome (NSTE-ACS) encourage the use of copeptin in combination 
with cTn specifically when no hs-cTn is available as an alternative strategy for rapid rule out.  
This recommendation is based on one randomized study and a meta-analysis.
4;16
  Finally, cost-
effectiveness is an important consideration, and it is necessary to demonstrate that the rapid 
diagnosis or rule-out of MI improves patient outcome, impacts the appropriate use of non-
invasive or invasive testing, and promotes efficient resource utilization in the emergency setting.   
 The Cardiovascular Round Table (CRT) of the ESC convened a dedicated two-day 
workshop (16-17 June 2016) to discuss advances in the early diagnosis of acute coronary 
syndrome (ACS) and the optimal application of early strategies in clinical practice to improve 
patient care.  This paper summarizes the key outputs from the workshop and provides an 
overview on current diagnostic strategies in early ACS, indicates the challenges in acute care that 
have arisen from the application of these highly sensitive tools, and identifies opportunities to 
enhance precision in acute care. 
 
HIGH SENSITIVITY CARDIAC TROPONIN IN THE EARLY DIAGNOSIS OF ACUTE 
CORONARY SYNDROME 
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 High sensitivity cTn assays are capable of measuring cTn above the level of detection 
and below the 99
th
 percentile upper reference limit (URL) in at least 50% of a reference 
population, with low imprecision (i.e., coefficient of variation [CV] ≤10% at the 99th percentile 
URL).
1;17
  The introduction of hs-cTn assays has enabled the rapid diagnosis (dynamic elevation 
above the 99
th
 percentile URL
4
) or rule-out of MI, typically in emergency department or other 
acute care settings, and it minimizes the need for prolonged (i.e., over 9 hours) repeat cTn 
measurements for many patients.  High-sensitive assays have better precision at the 99
th
 
percentile URL than earlier generation assays, which facilitates earlier detection of myocardial 
injury and permits reliable evaluation of cTn kinetics. 
 However, several clinical controversies have followed the introduction of hs-cTn assays, 
which have been reviewed in depth elsewhere.
1;5;17;18
  It is outside the scope of this manuscript to 
comprehensively revisit these issues, but the primary concerns involve the clinical translation of 
hs-cTn results in the context of assay characteristics.  The interpretation of mildly elevated hs-
cTn can be challenging, especially for hs-cTn I, since the 99
th
 percentile varies depending on the 
specific assay used.
3;19
  Additionally, manufacturer reported characteristics (i.e., the 99
th
 
percentile and the associated CV) have not been consistently replicated in clinical studies.
7
  The 
composition of the reference population is also of key importance, including the impact of 
different gender reference ranges, but the process for defining “normal” has been inconsistent 
across manufacturers.
1
  The selected “normal” population influences the 99th percentile reference 
value;
20
 thus, it is recommended that studies aiming to identify the 99
th
 percentile value should 
use specific criteria to define the population (e.g., age, estimated glomerular filtration rate 
[eGFR], natriuretic peptide [BNP or NT-proBNP] cut-off values, and health questionnaires).
20
  
Only two of the rapid rule-out algorithms include hs-cTn change criteria,
3
 but a dynamic rise and 
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fall pattern is an important factor for differentiating between acute and chronic myocardial 
injury.
6;17;21
   
 
APPLICATION OF EARLY DIAGNOSTIC STRATEGIES IN ACUTE MYOCARDIAL 
INFARCTION 
 Physicians caring for patients with acute chest pain are tasked with making a diagnosis, 
evaluating a patient’s risk level, and selecting the correct treatment or assessing a patient’s 
readiness for discharge.  It is important to recognize that non-cardiologists in emergency 
departments are often responsible for this triage.  In patients with suspected myocardial 
ischemia, very high baseline hs-cTn concentrations or large concentration changes (i.e. ≥5 ng/L 
at 1 hour for hs-cTnT) in conjunction with clinical evidence as required by the universal 
definition
4
 qualify for ruling in an MI.  It should be noted that in the TRAPID-AMI (High 
Sensitivity Cardiac Troponin T Assay for Rapid Rule-out of Acute Myocardial Infarction) study, 
the positive predictive value of the hs-cTnT 0-hour/1-hour algorithm for rule-in MI was 77.2%;
22
 
other common diagnoses meeting rule-in criteria were myocarditis, unstable angina, takotsubo 
cardiomyopathy, heart failure, arrhythmia, and symptoms of unknown origin.
22
  Aortic dissection 
or pulmonary embolism are other potential differential diagnoses.  Patients who meet rule-in 
criteria should undergo invasive coronary angiography according to the ESC NSTEMI 
guideline.
4
  While some patients who rule-in will not have MI but other diagnoses as above, 
coronary angiography is usually still needed for accurate diagnosis of these conditions.
4
  In 
specific cases, clinicians may use their clinical judgment not to proceed with angiography if the 
potential risks of the procedure outweigh the diagnostic benefits or if alternative diagnoses can 
be made with certainty by other means.  When angiography reveals non-obstructive 
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atherosclerosis or angiographically normal coronary arteries, further evaluation of MI with non-
obstructive coronary arteries (MINOCA) is indicated and may include additional invasive 
investigation, laboratory assays to identify potential causes of type-2 MI, echocardiography, 
cardiac magnetic resonance imaging, transesophageal echocardiography, or consideration of 
other diagnoses (e.g., dissection, Takotsubo cardiomyopathy, coronary vasospasm, myocarditis, 
cardioembolism).
23
 
 Importantly, a second blood draw is not always required in a patient with clearly elevated 
hs-cTn (>5 times the 99
th
 percentile of the upper reference limit)
4
 and typical clinical and 
electrocardiogram changes, as serial concentration changes do not improve the already high pre-
test probability for an MI;
24
 therefore, patients should be referred for acute management 
according to ESC guidelines.
4;25
  For other patient presentations, the diagnosis may be less clear.  
The ESC-CRT workshop participants proposed approaches that could be considered for the 
clinical evaluation of these patients, most of whom will present to the emergency department 
(Table 1, Figure 1).  The participants acknowledge that definitive evidence is currently lacking 
and emphasize the need to set a high priority for research in these areas.   
 
Patients with Symptoms and High Sensitivity Cardiac Troponin <99
th
 Percentile and Below 
the Limit of Detection 
 Patients falling within this category are generally considered to be low risk,
2
 and they 
have been proposed as candidates for early discharge from the emergency department.
2
  
However, such decisions can be premature leading to the fact that many such patients might not 
get the needed clinical care and medical treatment.  Patients with unstable angina can fall into 
this category (i.e., symptoms and hs-cTn <99
th
 percentile), since the diagnosis of unstable angina 
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generally requires anginal symptoms without evidence of cardiomyocyte necrosis.
6
  Thus, 
decisions to proceed with early discharge should include consideration of hs-cTn levels in 
conjunction with other clinical parameters (e.g., electrocardiogram, symptoms, risk factors, non-
cardiac etiology for symptoms).  Risk scores may also be helpful to assess prognosis and to 
guide clinical and therapeutic decision making
26
 (e.g., Thrombolysis in Myocardial Infarction 
[TIMI],
27
 Global Registry of Acute Coronary Events [GRACE],
28-31
 or History, 
Electrocardiogram, Age, Risk Factors, Troponin [HEART]
32-34
).  The HEART score was 
developed in patients presenting to the emergency department with chest pain.
32-34
  Use of the 
HEART score in conjunction with cTn reduced cardiac testing within 30 days, shortened length 
of hospital stays, and increased early discharge compared to guideline-directed usual care in 
patients presenting to the emergency department with ACS symptoms.
35
  Patients with negative 
serial hs-cTn below the limit of detection and a low-risk HEART score (or GRACE score) may 
be considered for discharge, whereas patients with negative serial hs-cTn below the limit of 
detection and a high-risk HEART score may be considered for admission to an observational 
unit, cardiac imaging, or stress testing.  However, it is acknowledged that a prospective, 
randomized trial is needed to test a specific strategy.  Such evidence coming from the 
randomized interventional Biomarkers in Cardiology (BIC)-8 trial is currently only available for 
an instant rule-out strategy in the presence of normal cTn concentration using a contemporary 
sensitive or hs-cTn assay in combination with a normal copeptin (CT-pro-vasopressin) value.
16
  
A cluster randomized trial using the GRACE score is underway in Australia (AGRIS)
36
 and in 
the United Kingdom (UKGRIS, ISRCTN registry number 29731761)
37
. 
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Patients with Symptoms and High Sensitivity Troponin <99
th
 Percentile but Above the 
Limit of Detection 
 Patients with hs-cTn results in this category may be considered higher risk than patients 
with hs-cTn below the 99
th
 percentile and below the limit of detection, since any elevation in cTn 
yields prognostic information.
38
  Patients with elevated hs-cTnI above a cut-off value (≥6 ng/L) 
(ARCHITECT i2000SR, Abbott Diagnostics, 99
th
 percentile 27 ng/L) in the Biomarkers in Acute 
Cardiac Care (BACC) study but without dynamic change had a higher 12-month mortality 
(8.2%) than patients who ruled-out (1%) or ruled-in (6.7%) for NSTEMI.
12
  Similar findings 
were observed for a cut-off value of 5 ng/L in a large prospective cohort in Scotland, 
strengthening the generalizability of this approach to risk stratification.
39;40
  
 Consensus has not yet been achieved with regard to whether the limit of detection or the 
limit of blank should be used for interpretation of hs-cTn results.  The limit of blank is the 
highest cTn concentration that is measured when a sample containing no cTn is tested, whereas 
the limit of detection is the lowest detectable cTn concentration that can be measured in a sample 
containing a low amount of cTn and can be distinguished from the limit of blank.
5
  hs-cTnT 
levels between the limit of blank and limit of detection are associated with a higher prevalence of 
cardiovascular risk factors, cardiac pathology, and worse prognosis.
41
  However, the imprecision 
of measurements at low levels (i.e., the limit of blank) is too great for clinical application.  
Reporting both limit of blank and limit of detection concentrations for hs-cTn and determining 
which limits are most informative for risk stratification, determining prognosis, and guiding 
treatment decisions should be research priorities.  Determining the correlation between risk 
scores and hs-cTn concentrations at the limit of blank or limit of detection may also help clarify 
the relevance of using these low levels of hs-cTn. 
11 
 
 The presence or absence of some patient characteristics should be taken into account in 
the interpretation of hs-cTn (e.g., renal impairment, atrial fibrillation, cardiac decompensation, 
advanced age, female gender, comorbidities, early and late presentation).  It is therefore critical 
to assess the clinical presentation, history, and electrocardiogram, as well as serial hs-cTn 
measurements to evaluate cTn kinetics.  Although thresholds of hs-cTn change to rule-in have 
been proposed,
13;42
 they are assay specific
2
 and the optimal threshold changes have not been 
determined.
43
  Additionally, application of change values may be limited in patients with low 
baseline hs-cTn values because of greater imprecision at low levels.
44
  Risk scores as described 
above should also be applied in this clinical scenario.  Other biomarkers may provide additional 
information about a patient’s potential risk, particularly natriuretic peptides (e.g., N-terminal pro-
B-type natriuretic peptide [NT-proBNP]) and to some extent also copeptin and growth 
differentiation factor-15 (GDF-15), as recommended in the ESC guidelines.
3;4
   
 Patients in this category may be appropriate candidates for early implementation of 
imaging strategies.
45
  Non-invasive imaging modalities (e.g., transthoracic, contrast, and/or stress 
echocardiography, cardiac magnetic resonance, nuclear myocardial perfusion, multi-detector 
computed tomography) to evaluate cardiac function, perfusion, and anatomy are recommended 
by current guidelines.
4
  Echocardiography is the most commonly used imaging modality, and 
although it cannot rule-out ACS, it can be helpful to exclude other disease and support the ACS 
diagnosis.  Coronary computed tomography angiography (coronary CTA) provides high and 
isotropic spatial resolution, and robust visualization of the coronary arteries.  It has a high 
sensitivity to detect stenosis; thus, a normal scan is extremely reliable to exclude stenosis, with a 
negative likelihood ratio of 0.022 in a meta-analysis of 30 studies representing 3422 patients.
46
  
As reviewed in the ESC guideline, outcomes are comparable for patients assessed with coronary 
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CTA versus standard care, but coronary CTA is associated with lower costs and shorter length of 
stay.
4
  Thus, coronary CTA “should be considered as an alternative to invasive angiography to 
exclude ACS when there is a low to intermediate likelihood of coronary artery disease and when 
cTn and/or electrocardiograms are inconclusive” (Class IIa, Level of Evidence A).4  However, 
the guideline acknowledges that none of the studies supporting the recommendation used hs-cTn 
assays.  In the open-label, randomized Better Evaluation of Acute Chest Pain with Coronary 
Computed Tomography Angiography (BEACON) trial, coronary CTA performed early (after the 
initial work-up) had similar rates of 30-day coronary revascularization and discharge from the 
emergency department, as well as length of stay compared to standard of care that included hs-
cTn testing.
47
  Direct medical costs and the proportion of patients with outpatient testing were 
lower in the coronary CTA group compared to standard of care.
47
  In a retrospective analysis of 
data from the ROMICAT II (Rule Out Myocardial Infarction/Ischemia Using Computer Assisted 
Tomography) trial, coronary CTA had a negative predictive value of 100% for ACS in patients 
with measurable but not elevated hs-cTnI and no evidence of significant stenosis or high risk 
plaque on coronary CTA.
45
  The rate of ACS was 69% in those patients with measurable but not 
elevated hs-cTnI and significant stenosis or high risk plaque on coronary CTA.
45
  The 
application of both hs-cTnI and coronary CTA in this retrospective analysis could have resulted 
in discharge for 60% of patients (i.e., with hs-cTnI below the limit of detection and negative 
coronary CTA) and triage of 16% of patients to receive early appropriate therapies (i.e., hs-cTnI 
>99
th
 percentile or positive coronary CTA).
45
  Whether coronary CTA can be useful in the early 
evaluation of ACS depends on its timely availability, both of equipment and appropriate 
technical expertise to obtain quality images.  Cardiac magnetic resonance (CMR) imaging is a 
guideline recommended strategy to assess perfusion and wall motion abnormalities, as well as 
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the presence of myocardial edema in acute myocardial infarction as well as necrotic and scarred 
myocardium.
48
  CMR can well distinguish chest pain due to ACS from that of other causes.
4
  
While the clinical utility in emergency settings may be hampered by a limited local access to an 
MRI scanner and trained personnel, it can reliably diagnosis acute coronary syndrome
49
 and can 
even reduce the cost of the diagnostic workup.
50
  CMR is especially useful in patients with 
suspected acute myocardial injury due to myocarditis
51
 or stress-induced cardiomyopathies,
52
 
and in patients with MINOCA.
23;53;54
 
 
Patients with Symptoms and High Sensitivity Troponin >99
th
 Percentile Without Dynamic 
Change 
 The clinical history should be carefully reviewed for patients presenting with hs-cTn 
above the 99
th
 percentile but without dynamic changes to estimate the onset of symptoms and to 
allow for assessment of whether the patient may be an early or late presenter, since early 
presenters may have had insufficient time to exhibit change and 10% to 26% of patients with MI 
may not demonstrate delta cTn criteria possibly because they present late during the cTn plateau 
phase.
55;56
  Risk scores may also be helpful in the evaluation of these patients.
26
  Repeat hs-cTn 
testing should be performed in early presenters according to guideline recommended algorithms.
4
  
Late presenters with high-risk scores may warrant more aggressive evaluation, either with 
imaging or angiography, depending on the clinical assessment and risk level.  In high-risk 
patients, there is no reasonable alternative to angiography.   
 Patients in whom an early or late presentation has been excluded should be evaluated for 
other causes of cTn release (e.g., heart failure, renal impairment, pulmonary embolism, 
arrhythmia, valvular disease, shock, anemia, hypertension, defibrillator shocks, contusion, 
14 
 
myocarditis, cardiotoxic agents
57;58
).  Recent publications suggest that these presentations do not 
necessarily represent MI, but rather, stable myocardial injury.
6
  Specific diagnostic criteria and 
evidence based treatment guidelines are absent for this group of patients.  Thus, until evidence 
specific for this presentation are available, these patients should undergo further testing and 
treatment appropriate for the underlying cause, recognizing that cTn release, even if not 
diagnostic for ACS, is associated with greater risk for poor outcomes.
4;59;60
  Crude mortality in 
these patients is high,
12
 but mortality seems to be related to comorbidities rather than ACS 
events.  Unstable angina could also be a factor in these patients who have chronically elevated 
cTn for other reasons (i.e., chronic heart failure, renal impairment) if they have symptoms 
consistent with unstable angina and no dynamic change patterns.  Imaging strategies as described 
above may be particularly relevant in patients with hs-cTn values above the 99
th
 percentile that 
are indeterminate for a NSTEMI diagnosis. 
 
Patients with Symptoms and High Sensitivity Troponin >99th Percentile and Dynamic 
Change but without Coronary Plaque Rupture/Erosion/Dissection 
These patients with type 2 MI fulfill the diagnostic criteria of MI but share a different 
pathophysiologic mechanism than type 1 MI, which is characterized by plaque rupture, erosion 
or dissection.
57
 Type 2 MI is thought to result from an imbalance between oxygen supply and 
demand, regardless of the presence or absence of an obstructive coronary lesion.
57
  
Differentiation of patients with plaque erosion, thrombus development, and micro-embolisation 
may be difficult or impossible without invasive advanced imaging (for example OCT) and such 
patients may have apparently trivial or no coronary obstructive disease, yet they could have 
suffered a type 1 MI.  The prevalence of type 2 MI varies widely across studies according to the 
15 
 
heterogeneity of definitions.
61
 Although there are several differences regarding baseline 
characteristics of patients and troponin kinetics, prospective differentiation of type 2 from type 1 
MI is almost impossible without knowledge of coronary anatomy.
62
 However, differentiation is 
important as type 2 MI is associated with mortality rates at least as high as encountered with type 
1 MI.
63;64
 In addition, sparse data are available on the appropriate pharmacological treatment, 
particularly the balance between bleeding risk and benefits.  
 
CONCLUSION  
 The availability of highly sensitive and precise tools for the diagnosis of AMI has the 
potential to improve patient care by facilitating faster diagnosis and implementation of evidence-
based therapies or interventions.  It may also benefit non-ACS patients by quickly ruling out MI, 
allowing physicians to confidently discharge patients from the emergency department, pursue 
other diagnoses for chest pain, or appropriately redirect limited resources in the emergency 
setting.  However, careful inspection of cTn based rapid algorithms brings attention to the 
evidence gaps, where the diagnosis remains inconclusive for a substantial proportion (up to 44%) 
of patients; additional strategies are needed for this group.  The only strategy tested in a 
randomized, prospective study is the combination of cTn and copeptin with limited evidence for 
the use of hsTn assays.  These areas of uncertainty should be assigned a high priority for 
research.  As the field advances, evidence on cost-effectiveness must also be generated to inform 
optimal implementation of early detection strategies.  Use of early diagnostic tools that lead to 
uncertainty, and therefore use of unnecessary tests, will not be supported by payers.  In contrast, 
tools that effectively identify high-risk patients, leading to appropriate interventional or 
prevention strategies that impact outcomes, will be clinically valuable.  
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Figure 1.  Proposed Risk Based Assessment of Patients Indeterminate for Acute Myocardial 
Infarction 
This figure presents a risk-based flow for evaluation of patients who fall in the “indeterminate” 
category for acute myocardial infarction.  Patients considered low-risk by hs-cTn evaluation can 
be further risk stratified using risk scores, then subsequent decisions (e.g., discharge, 
observation, further evaluation) made based on this risk assessment.  A variety of laboratory and 
imaging tests, as well as risk scores can be implemented to further delineate the risk of patients 
initially at intermediate risk.  The highest risk patients should generally be considered for 
coronary angiography or advanced imaging, with other evaluations as appropriate to determine 
the type of MI or other cardiac etiology. 
*According to the Biomarker Study Group of the ESC Acute Cardiovascular Care Association, 
“This combination provides incremental diagnostic value as compared to the use of a single 
conventional cTn concentration, but provides no or only minor incremental value when using hs-
cTn assays.  The limitations of this strategy include the complexity of an additional biomarker, 
low positive predictive value for the combination of an elevated copeptin with a negative cTn, 
and the need for an additional analyser.”3  
AF, atrial fibrillation; CKD, chronic kidney disease; CTA, computed tomography angiography; 
GDF-15, growth differentiation factor-15; GRACE, Global Registry of Acute Coronary Events 
score; HEART, History, Electrocardiogram, Age, Risk Factors, Troponin score; HF, heart 
failure; hs-cTn, high-sensitivity cardiac troponin; LOD, limit of detection; MINOCA, MI with 
non-obstructive coronary arteries NT-proBNP, N-terminal pro-B-type natriuretic peptide; TIMI, 
Thrombolysis in Myocardial Infarction score 
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 Table 1.  Clinical Scenarios, Potential Approaches, and Need for Research 
Clinical Scenario Potential Approaches Areas of Uncertainty Future Research 
Chest pain or symptoms 
suggestive of myocardial 
ischaemia with hs-cTn <99
th
 
percentile and below the limit 
of detection
2
 
 Review clinical parameters 
(ECG, symptoms, risk 
factors) 
 Use risk scores26;32-35 (e.g., 
HEART, GRACE, TIMI) 
 Low risk patients:  
discharge or further 
investigate non-cardiac 
causes 
 High-risk patients:  chest 
pain observation unit, 
repeat hs-cTn (early rule-
out protocols), obtain 
cardiac imaging or stress 
 Which score is optimal to 
aid in risk assessment in 
this specific patient 
population 
 Do established thresholds 
that define low and high 
risk translate to this patient 
population 
 Does a risk score approach 
combined with hs-cTn 
improve the specificity and 
sensitivity of detecting ACS 
and improve patient 
outcome? 
AGRIS
36
 and UK Grace Risk 
Score Intervention Study
37
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Clinical Scenario Potential Approaches Areas of Uncertainty Future Research 
test  Definition of unstable 
angina in the era of hs-cTn 
Chest pain or symptoms 
suggestive of myocardial 
ischaemia with hs-cTn <99
th
 
percentile but above the limit of 
detection
2;12
 
 Repeat hs-cTn (early rule-
out protocols), chest pain 
observation unit, obtain 
cardiac imaging (coronary 
CTA) or stress test, risk 
assessment (e.g., risk 
scores, NT-proBNP, co-
peptin, GDF-15)
3;4;45
 
 Evaluate for comorbidities 
(e.g., atrial fibrillation, 
heart failure, chronic 
kidney disease) 
 Assess symptom onset and 
 hs-cTn kinetics and 
potential influence of 
presentation time 
 Thresholds of hs-cTn 
change that signify 
myocardial necrosis at low 
baseline hs-cTn levels 
 Prospective analysis of 
utility of cardiac imaging 
strategies on top of hs-cTn 
in this population 
 ROC analyses to find 
optimal thresholds for hs-
cTn change criteria 
 hs-cTn kinetics especially 
in patients with 
comorbidities commonly 
encountered in practice 
Table 1.  Clinical Scenarios, Potential Approaches, and Need for Research (continued) 
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Clinical Scenario Potential Approaches Areas of Uncertainty Future Research 
time of presentation 
Chest pain or symptoms 
suggestive of myocardial 
ischaemia with hs-cTn >99
th
 
percentile without dynamic 
change
2
 
 Serial hs-cTn (1, 2, or 3 
hour protocols) in early 
presenters
4
 
 Chest pain observation unit, 
obtain cardiac imaging 
(coronary CTA) or stress 
test, risk assessment (e.g., 
risk scores, NT-proBNP, 
co-peptin, GDF-15) 
 Late presenters with high-
risk scores should undergo 
angiography or imaging (as 
appropriate for risk 
level)
55;56
 
 Diagnosis and treatment 
guidelines for non-ACS 
myocardial injury 
 Better characterize stable 
myocardial injury 
 Determine treatment 
approaches to reduce 
myocardial injury and 
improve outcomes in these 
patients 
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Clinical Scenario Potential Approaches Areas of Uncertainty Future Research 
 Evaluate for comorbidities 
(e.g., arrhythmia, heart 
failure, chronic kidney 
disease, and others)
23;57;58
 
Chest pain or symptoms 
suggestive of myocardial 
ischaemia with hs-cTn >99
th
 
percentile and dynamic change 
but without coronary plaque 
rupture, erosion, or dissection
2
 
 Invasive advanced imaging 
or coronary angiography to 
differentiate type 2 from 
type 1 MI
57
 
 Treatment strategies 
 Net benefit from 
antiplatelet or anticoagulant 
therapy (potential for 
benefit vs. bleeding risk) 
 Determine treatment 
approaches to improve 
outcomes in these patients 
CTA, computed tomography angiography; GDF-15, growth differentiation factor-15; hs-cTn, high-sensitivity cardiac troponin; MI, 
myocardial infarction; NT-proBNP, N-terminal pro-B-type natriuretic peptide 
 
 
